vitb3
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| vitb3 [2023/07/05 11:09] – [Pellagra] gary1 | vitb3 [2025/09/29 00:10] (current) – [Actions of pharmacologic doses of nicotinamide] gary1 | ||
|---|---|---|---|
| Line 81: | Line 81: | ||
| * nicotinamide suppressed interleukin (IL)-8 production at the mRNA and protein levels through modulation of the nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) pathways in HaCaT cells and primary keratinocytes stimulated by Propionibacterium acnes, the aetiological agent causing inflammatory acne vulgaris. Nicotinamide downregulated the expression of IL-6, IL-10, monocyte chemoattractant protein-1 and tumor necrosis factor (TNF)-α in UV-irradiated keratinocytes (([[https:// | * nicotinamide suppressed interleukin (IL)-8 production at the mRNA and protein levels through modulation of the nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) pathways in HaCaT cells and primary keratinocytes stimulated by Propionibacterium acnes, the aetiological agent causing inflammatory acne vulgaris. Nicotinamide downregulated the expression of IL-6, IL-10, monocyte chemoattractant protein-1 and tumor necrosis factor (TNF)-α in UV-irradiated keratinocytes (([[https:// | ||
| * it is an inhibitor of the nuclear enzyme poly(adenosine diphosphate-ribose [ADP]) polymerase [PARP], which plays a significant role in DNA repair, maintenance of genomic stability, and cellular response to injury including inflammation and apoptosis | * it is an inhibitor of the nuclear enzyme poly(adenosine diphosphate-ribose [ADP]) polymerase [PARP], which plays a significant role in DNA repair, maintenance of genomic stability, and cellular response to injury including inflammation and apoptosis | ||
| + | ***may reduce [[steatohepatitis|MASLD]]** | ||
| + | * microRNA-93 (miR-93), which is expressed in the liver, is a key genetic regulator in the development and progression of MASLD | ||
| + | * niacin suppresses miR-93 and thus may reduce MASLD | ||
| ***oral doses of 500mg bd in humans have been shown to:** | ***oral doses of 500mg bd in humans have been shown to:** | ||
| * reduce solar keratoses by ~20% over 12 months and to reduce incidence of BCCs and SCCs as well as repair UV-mediated skin damage via increasing activity of DNA repair systems | * reduce solar keratoses by ~20% over 12 months and to reduce incidence of BCCs and SCCs as well as repair UV-mediated skin damage via increasing activity of DNA repair systems | ||
vitb3.txt · Last modified: 2025/09/29 00:10 by gary1